Anemia Drugs Market Report 2026

The anemia drugs market size has grown strongly in recent years. It will grow from $15.77 billion in 2025 to $16.96 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to iron deficiency prevalence, chronic kidney disease growth, hospital transfusion usage, maternal anemia incidence, dietary deficiency.

The anemia drugs market size is expected to see strong growth in the next few years. It will grow to $22.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to aging population growth, chronic disease anemia management, injectable iron adoption, home healthcare expansion, preventive supplementation. Major trends in the forecast period include rising use of erythropoiesis-stimulating agents, growth of intravenous iron therapy, expansion of home-based anemia management, increased focus on chronic disease anemia, shift toward combination supplement therapy.

The growing emphasis on personalized medicine is expected to drive the expansion of the anemia drugs market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and medical decisions according to an individual’s genetic profile, lifestyle, and environment. The rising emphasis on personalized medicine is attributed to advances in genomic sequencing, which enable more accurate identification of unique genetic variations associated with disease and treatment response. Personalized medicine facilitates anemia drug development by allowing tailored therapies based on individual genetic profiles, enhancing drug effectiveness, and reducing adverse effects for improved patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition, a U.S.-based non-profit organization, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases in 2023, a notable increase from 6 in 2022. Consequently, the growing emphasis on personalized medicine propels the growth of the anemia drugs market.

Major companies operating in the anemia drugs market are concentrating on innovative drug developments, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), to enhance iron metabolism and stimulate red blood cell production for more effective anemia treatments. Oral HIF-PHI (Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors) are a class of oral medications that inhibit prolyl hydroxylase enzymes, which are involved in regulating the hypoxia-inducible factor (HIF) pathway. For example, in February 2023, GSK plc, a UK-based pharmaceutical company, introduced Jesduvroq, a therapy aimed at improving red blood cell production and managing anemia in adult patients with chronic kidney disease. This advanced anemia drug system offers improved iron metabolism, increased red blood cell production, and personalized treatment options. Jesduvroq is highly effective, enhancing red blood cell production and treating anemia in chronic kidney disease patients by optimizing iron metabolism for better therapeutic outcomes.

In May 2023, Akebia Therapeutics, a US-based biopharmaceutical company, formed a partnership with Medice Arzneimittel Pütter GmbH & Co. KG to commercialize Vafseo for anemia in Europe and Australia. Through this collaboration, Akebia Therapeutics and Medice Arzneimittel Pütter aim to promote sustainable growth and improve the availability of Vafseo for anemia treatment through greater accessibility and innovation. Medice Arzneimittel Pütter GmbH & Co. KG is a Germany-based pharmaceutical company specializing in anemia therapies and prescription medicines.

Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, BioLineRx Ltd., Bluebird Bio Inc.

North America was the largest region in the anemia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the anemia drugs market by increasing the cost of imported APIs, iron compounds, and injectable formulation materials used in treatment manufacturing. These impacts have been most pronounced in ESA and parenteral iron segments, where production complexity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to globally diversified sourcing, while Asia Pacific manufacturers have faced sustained cost pressure on raw materials. Rising tariff related expenses have influenced pricing strategies, procurement planning, and product availability across hospital and retail channels. However, tariffs have supported domestic supplement production, expanded generic anemia drug manufacturing, and improved long term supply chain stability.

The anemia drugs market research report is one of a series of new reports that provides anemia drugs market statistics, including anemia drugs industry global market size, regional shares, competitors with a anemia drugs market share, detailed anemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia drugs industry. This anemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anemia drugs are medications used to address low levels of red blood cells (RBCs) or hemoglobin in the blood. These medications enhance oxygen transport throughout the body and alleviate fatigue, targeting the underlying causes of anemia, such as iron deficiency, chronic illnesses, or kidney conditions.

The main types of anemia drugs include dietary supplements and medicines. Dietary supplements are products taken orally that provide essential nutrients such as iron, folic acid, or vitamin B12 to help prevent or manage anemia. The various therapy options include oral iron therapy, parenteral iron therapy, red blood cell transfusion, and other supportive treatments. The different types of anemia include iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia, and other forms of anemia. These drugs are distributed through multiple channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The end-users include clinics, healthcare facilities, and home healthcare providers.

The anemia drugs market consists of sales of androgens, hydroxyurea, luspatercept and sotatercept. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.